Dividend Stocks Outperforming Market in 2026

Johnson & Johnson and Amgen lead dividend stocks with strong growth potential despite near-term challenges.

8 cards · 1m 30s · tap to begin

From · · · 1m 30s

Dividend Stocks Outperforming Market in 2026

Johnson & Johnson and Amgen lead dividend stocks with strong growth potential despite near-term challenges.

In brief

Johnson & Johnson and Amgen lead dividend stocks with strong growth potential despite near-term challenges. Johnson & Johnson and Amgen offer stable dividend growth with long-term resilience amid regulatory and market headwinds. Originally reported by The Motley Fool.

Market Resilience and Risks

26_10_27 A balance sheet with a fountain pen _MD Dload Getty Images -1280x853-c533c3e

Broader equities remain resilient despite potential macroeconomic problems and geopolitical tensions leading to market crashes.

Johnson & Johnson Overview

26_10_29 A person holding up a king chess piece _MF Dload GettyImages-1441867236-1280x853-c533c3e

Johnson & Johnson outperformed the market this year with strong financial results but faces medtech challenges including a Class 1 recall for Impella heart pump.

Johnson & Johnson's Medtech Issues

Johnson & Johnson's cardiovascular segment faces lower demand due to safety and efficacy questions with Impella heart pump under Class 1 recall in the U.S.

Johnson & Johnson's Growth Drivers

Johnson & Johnson's innovative medicines segment shows growth potential with new products like ICOTYDE for plaque psoriasis and OTTAVA robotic-assisted surgery system.

Johnson & Johnson's Dividend Safety

Person standing in pharmacy aisle holding mouthwash and searching on phone

Johnson & Johnson has 64 years of consecutive dividend increases with a 1.93% dividend yield and AAA rating from S&P Global.

Amgen's Regulatory Challenges

Amgen faces regulatory pressure on Tavneos due to safety risks and insufficient efficacy evidence with U.S. Food and Drug Administration pushing for removal from market.

Amgen's Revenue and Growth

Amgen reported second-quarter revenue of $10.1 billion with 10% year-over-year growth despite losing U.S. patent exclusivity for denosumab.

Amgen's Future Prospects

Amgen's pipeline includes promising candidates like MariTide for weight loss and Tezspire for asthma with strong long-term growth potential.

The one thing

Johnson & Johnson and Amgen offer stable dividend growth with long-term resilience amid regulatory and market headwinds.

Read the original on The Motley Fool

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on jnj and related topics.